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Purpose: To analyze the contributions of cytochrome P4501B1 (CYP1B1) mutations to primary congenital glaucoma
(PCG) in Spanish patients.
Methods: We analyzed, by polymerase chain reaction (PCR) DNA sequencing, the presence of promoter (−1 to −867)
and exon CYP1B1 mutations in 38 unrelated Spanish probands affected by PCG. Functional analysis of nine identified
mutations  was  performed  measuring  ethoxyresorufin  O-deethylation  activity  and  CYP1B1  stability  in  transiently
transfected human embryonic kidney 293T (HEK-293-T) cells.
Results: We found a total of 16 different mutations in 13 (34.2%) index cases. The identified mutations included nine
missense and three nonsense nucleotide changes, three small deletions, and a short duplication. Eleven probands were
compound heterozygotes and two were heterozygotes. Six of the identified mutations were novel (A106D, E173X, F261L,
E262X, W341X, and P513_K514del). Mutations T404fsX30 and R355fsX69 were the most prevalent among index cases
and were detected in six (23.0%) and three (11.5%) patients, respectively. Functional analysis showed that the three
nonsense mutants assayed (E173X, E262X, and W341X) and F261L were null alleles. Of the remaining mutants, four
(P52L, G61E, Y81N, and E229K) showed catalytic activities ranging from 20% to 40% of wild-type CYP1B1 and high
protein instability. Mutation P400S showed normal catalytic activity and moderate instability. These five mutants were
classified as hypomorphic alleles. Patients carrying two null alleles showed severe phenotypes featured by very early PCG
onset usually at birth or in the first month of life (0.6±0.9 months). Incomplete penetrance was detected in patients carrying
hypomorphic alleles.
Conclusions: Our data indicate that approximately one-third of Spanish patients with PCG carry loss-of-function CYP1B1
and show that null alleles are associated with the most severe phenotypes. Hypomorphic alleles may contribute to some
cases of incomplete penetrance.
Primary congenital glaucoma (PCG; OMIM 231300) is
usually  transmitted  as  an  autosomal-recessive  trait  with
incomplete  penetrance  [1,2].  The  disease  is  featured  by
developmental defects of the trabecular meshwork (TM) and
the anterior chamber angle of the eye, which leads to aqueous
outflow obstruction, elevated intraocular pressure (IOP), and
optic nerve damage [3]. PCG is the most common childhood
glaucoma,  which  is  observed  in  the  neonatal  or  infantile
period, and is an important cause of visual loss in children.
Parental consanguinity is frequently reported, mainly in Arab
populations [4-6]. Its incidence has been reported to range
from 1:1250 and 1:2500 births in inbred Slovakian Gypsy
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[7]  and  Saudi  Arabian  populations  [2],  respectively,  to
1:5000 and 1:10000 births in Western countries [8].
Three PCG loci have been mapped, GLC3A (2p21) [9],
GLC3B (1p36) [10], and GLC3C (14q24.3) [11]. To date, only
the gene linked to the GLC3A locus, cytochrome P4501B1
(CYP1B1;  OMIM  601771),  has  been  identified  [12].
Nonetheless,  mutations  in  myocilin  (MYOC;  OMIM
601652)  [13,14]  and  forkhead  box  C1  (FOXC1;  OMIM
601090) [15] have also been reported in some PCG cases.
Although  the  mutations  in  CYP1B1  are  the  main  known
genetic  cause  of  this  type  of  glaucoma  [16]  in  different
worldwide populations [4,6,17-22], the role of this gene in
Spanish patients has not yet been investigated. Ninety-two
CYP1B1  mutations  have  now  been  implicated  in  the
pathogenesis  of  PCG  including  missense,  nonsense,
frameshift mutations, and small insertions and deletions (the
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Most missense mutations map to highly conserved functional
regions of the protein. CYP1B1 mutations are also present in
certain  families  where  PCG  and  primary  open-angle
glaucoma  (POAG)  coexist  [5,21,23],  in  non-Mendelian
POAG cases [24-26], and in monogenic anterior segment
dysgenesis like Peters’ anomaly [27,28] and Rieger’s anomaly
[29]. This gene has also been reported to act as a modifier gene
in juvenile open-angle glaucoma [30]. The wide range of
glaucoma  phenotypes  associated  with  CYP1B1  mutations
suggests  that  it  plays  a  key  role  in  the  physiology  and
development of the eye [31].
CYP1B1  encodes  a  member  of  the  cytochrome  P450
superfamily, subfamily I, and is composed of three exons with
the translated region beginning at the 5′ end of the second
exon. The CYP1B1 protein is a membrane-bound monomeric
mixed function monooxygenase. This cytochrome has been
proposed to participate in iridocorneal angle development
[32], thus alteration of CYP1B1 catalytic activity could impair
the  morphogenesis  of  the  outflow  angle,  leading  to  IOP
elevation  and  glaucoma.  In  fact,  partial  loss-of-function,
reduced  stability,  and  diminished  localization  in  the
mitochondria have been described for CYP1B1 mutations by
a few previous functional reports [6,33-35].
We have herein investigated for the first time the role of
CYP1B1 mutations in a group of 38 unrelated Spanish families
with PCG. We found 16 different loss-of-function CYP1B1
mutations present in approximately one-third of the index
cases. Our data show that complete loss of CYP1B1 catalytic
activity is associated with the most severe phenotypes and
indicate the influence of modifier genes and/or environmental
factors in the phenotypic expression, particularly in subjects
carrying hypomorphic CYP1B1 alleles.
METHODS
Subjects: A total of 39 patients (69 eyes) with PCG from 38
different families were recruited for genetic analysis. Thirty-
eight  patients  were  Spanish  natives  with  Spanish  family
names, although the father of one of the index cases (PCG 41)
was German. Patients with pediatric glaucoma, which was
either related to other ocular disorders or associated with
systemic  abnormalities,  were  excluded.  In  addition,  70
unaffected patients’ relatives were studied. The study was
approved by the Ethics Committees for Human Research of
the  hospitals  involved  (Hospital  General  Universitario  de
Alicante,  Alicante,  Spain,  Hospital  San  Carlos,  Madrid,
Spain,  Hospital  La  Paz,  Madrid,  Spain,  and  Fundación
Jiménez Díaz, Madrid, Spain) and followed the tenets of the
Declaration of Helsinki. Informed consents were obtained
from all subjects included in the study. Clinical data were
retrospectively  reviewed.  All  subjects  were  clinically
evaluated  by  glaucoma  specialists.  The  ophthalmic
examination included slit lamp biomicroscopy, gonioscopy,
measurement  of  IOP  and  ophthalmoscopy.  The  clinical
diagnosis  included  at  least  two  of  the  following  clinical
features: increased corneal diameter (>12 mm) along with
elevated  IOP  (>21  mmHg  or  >16  mmHg  under  general
anesthesia) and/or Haab’s striae, corneal edema, and optic
disc changes. The age at diagnosis ranged from 0 to 28.5
months,  although  in  one  case  the  diagnosis  was  delayed.
Intraocular  pressure  was  measured  using  the  Perkins
applanation tonometer generally under halothane anesthesia
as soon as the child was sufficiently anesthetized to check
intraocular pressure (during the first 10 min after induction
and before tracheal intubation). Older and more cooperative
children were assessed using a slit lamp for tonometry with a
Goldman applanation tonometer. A control group composed
of 325 patients from whom glaucoma was ruled out was used
to  screen  for  the  presence  of  novel  CYP1B1  mutations
identified in PCG patients. These subjects were recruited from
among those who attended the clinic for conditions other than
glaucoma including cataracts, floaters, refractive errors, and
itchy eyes.
Mutation analysis: Genomic DNA was extracted from the
peripheral leukocytes of all the subjects studied using the
QIAamp DNA Blood Mini Kit (Qiagen, Hilden, Germany)
according  to  the  manufacturer’s  protocol.  The  translated
(exons  II  and  III),  untranslated  (exon  I),  and  promoter
(nucleotides −1 to −867) regions of CYP1B1 were amplified
as previously described [26]. Terminator cycle sequencing
was  performed  using  the  BigDye  (v3.1)  kit  (Applied
Biosystems, Foster City, CA), and the products of sequencing
reactions  were  analyzed  in  an  automated  capillary  DNA
sequencer  (ABI  Prism  3130  genetic  analyzer;  Applied
Biosystems). Mutations were confirmed by sequencing the
cDNA strand and by independent sequencing in a second
DNA  sample.  The  haplotypes  for  the  four  SNPs  (R48G,
A119S, V432L, and N453S) were determined by segregation
analysis.
Site-directed  mutagenesis: The  cDNA  encoding  wild-type
CYP1B1  was  obtained  from  Invitrogen  (cDNA  clone  ID
4662252;  Carlsbad,  CA)  and  was  used  as  a  template  to
produce different CYP1B1 mutations found in PCG patients
using  the  QuikChange  site-directed  mutagenesis  kit
(Stratagene, La Jolla, CA). The specific polymerase chain
reaction (PCR) primers used for mutagenesis are presented in
Table 1. The background haplotype of the wild-type cDNA
clone  for  the  four  common  coding  SNPs  (R48G,  A119S,
V432L,  and  N453S)  was  RAVN.  Therefore,  this  was  the
background  haplotype  of  all  the  cloned  mutations.  The
cDNAs  encoding  the  wild-type  protein  and  the  different
mutant CYP1B1 forms were cloned into the Xba-BamHI sites
of the pcDNA3.1-myc-His mammalian expression vector as
previously described [36].
Cell  transfections:  The  human  embryonic  kidney  293T
(HEK-293T)  cell  line  was  obtained  from  the  ATCC
(American type Culture Collection, Manassas, VA), and it
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418was  maintained  in  Dulbecco’s  modified  Eagle’s  medium
(DMEM) supplemented with 10% fetal bovine serum (FBS)
and antibiotics (penicillin and streptomycin; Invitrogen) at
37 °C in a fully humidified 5% CO2 atmosphere. Transient
plasmid transfections were performed with 400 ng of total
DNA using the Superfect Transfection Reagent (Quiagen,
Valencia,  CA)  as  previously  described  [37].  To  assess
transfection efficiency, the cDNA constructs encoding the
different CYP1B1 mutants were cotransfected with 200 ng of
a  cDNA  construct  encoding  the  green  fluorescent  protein
(GFP) from the jellyfish, Aequorea victoria. The GFP cDNA
was cloned into the pcDNA3.1 vector. GFP was detected by
western blot using an anti-GFP monoclonal antibody (Santa
Cruz Biotechnology, Santa Cruz, CA).
CYP1B1  enzymatic  assay:  The  time  course  of  CYP1B1
activity was analyzed by determining the ethoxyresorufin O-
deethylation (EROD) activity in transfected HEK-293T cells.
7-Ethoxiresorufin substrate (400 nM) dissolved in PBS was
added to cells in culture 13–15 h after transfection. After 2 h
at 37 °C, the reaction product (resorufin) that secreted into the
culture  medium  was  measured  in  triplicate  aliquots  by  a
fluorometric assay [38] using a SpectraMax® GEMINI XS
spectrofluorometer  (Molecular  Devices  Corp,  Sunnyvale,
CA)  at  530  nm  (excitation)  and  590  nm  (emission).
Endogenous CYP1B1 activity was estimated in control assays
performed in HEK-293T cells transiently transfected with the
non-recombinant pcDNA3.1 vector. The background activity
was subtracted from all the enzymatic assays performed either
with wild-type or mutant CYP1B1. Three independent assays
for each mutant were performed.
CYP1B1  stability  assay:  Protein  stability  was  studied  by
western  blot  of  transfected  cells  incubated  with
cycloheximide  (10  µg/ml)  for  0  h,  2  h,  5  h,  and  8  h.
Cycloheximide was added 13–15 h after transfection. After
cycloheximide treatment, adhered cells were washed twice
with 1 ml of DMEM followed by an addition of 200 µl of lysis
buffer containing proteinase inhibitors. Collected cells were
vortexed for 30 s at the maximum speed, incubated for 30 min
on ice, and sonicated for 10 s (cycle 0.5 s). Aliquots of cell
lysates  were  treated  with  loading  buffer  containing  β-
mercaptoethanol, boiled for 10 min, and fractionated by SDS–
PAGE. Analytical 10% PAGE in the presence of SDS was
performed using the Mini-PROTEAN III gel electrophoresis
system (Bio-Rad, Hercules, CA). Gels were transferred onto
Hybond  ECL  nitrocellulose  membranes  (Amersham,
Uppsala,  Sweden)  for  immunodetection.  A  commercial
mouse  monoclonal  anti-myc  antibody  (Santa  Cruz
Biotechnology) was used as the primary antibody diluted at
1:500. A horseradish peroxidase-conjugated antibody against
mouse IgG (Pierce Biotechnology, Rockford, IL) was diluted
at 1:1000. Chemiluminescence detection was performed with
Supersignal Dura Western Blot reagents (Pierce). The data
from triplicate independent experiments were obtained. The
amount of CYP1B1 protein was determined by densitometry,
and the relative amounts at the different time points were
expressed as a percentage of levels at time 0 h.
Statistical analysis: Significance of the difference in age and
IOP among patients was determined by the t-test. Data were
statistically analyzed by using SigmaStat 2.0 software (SPSS
Inc., Chicago, IL).
TABLE 1. PRIMER SEQUENCES USED IN THIS STUDY.
Primer set Primer sequence (5′→3′)
P52L F: GGTCCGCGCCCCTGGGCCCGTTTGC
R: GCAAACGGGCCCAGGGGCGCGGACC
G61E F: GTGGCCACTGATCGAAAACGCGGCGGCG
R: CGCCGCCGCGTTTTCGATCAGTGGCCAC
Y81N F: CTGGCGCGGCGCAACGGCGACGTTTTC
R: GAAAACGTCGCCGTTGCGCCGCGCCAG
E173X F: CGGCTCTAGAATGGGCACCAGCCTCAGCCCG
R: CGCAGGATCCGCGCTCAGCACGTGGCCCTCGAGG
E229K F: CTGCTCAGCCACAACAAAGAGTTCGGGCGCAC
R: GTGCGCCCGAACTCTTTGTTGTGGCTGAGCAG
F261L F: CCGTTTTCCGCGAATTAGAGCAGCTCAACCGCA
R: TGCGGTTGAGCTGCTCTAATTCGCGGAAAACGG
E262X F: CGGCTCTAGAATGGGCACCAGCCTCAGCCCG
R: CGCAGGATCCGCGAATTCGCGGAAAACGGTGCGC
P400S F: TTGTGCCTGTCACTATTTCTCATGCCACCACTGCC
R: GGCAGTGGTGGCATGAGAAATAGTGACAGGCACAA
R469W F: TTTCAGTGGGCAAAAGGTGGTGCATTGGCGAAGAA
R: TTCTTCGCCAATGCACCACCTTTTGCCCACTGAAA
In the "Primer sequence" column, "F" indicates forward primer and "R" indicated reverse primer.
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419Mutation nomenclature: Mutations were named based on the
cDNA reference sequence U03688 [39]. The first nucleotide
of the transcription initiation site is denoted as nucleotide +1
according to Tang and coworkers [40].
RESULTS
Clinical  phenotype  of  patients:  To  investigate  the  role  of
CYP1B1 mutations in the development of PCG in Spanish
patients, we retrospectively studied a total of 38 unrelated
families  affected  by  the  disease.  PCG  segregated  as  an
autosomal  recessive  trait  in  37  families  and  showed  a
dominant or pseudo-dominant pattern in one family (PCG 35).
Twenty-eight  patients  (72%)  were  male,  and  11  patients
(28%) were female. The disease was bilateral in 30 patients
(77%). At the time of diagnosis, ages ranged from 1 day to 36
months (median 6.5 months). The diagnosis was delayed in
one  patient  (PCG  44).  Suspicion  of  primary  congenital
glaucoma  was  based  on  cornea  enlargement  (100%)  and
associated  hazy  corneas  (80%),  photophobia  and
blepharospasm (72%), and tearing (64%). Horizontal corneal
diameters, measured under general anesthesia, ranged from
12 to 15 mm with an average of 13.25 ±0.9 mm. The mean
preoperative  intraocular  pressure  before  the  first  surgical
intervention was 25.4±7.1 mmHg. The average cup/disc size
ratio was 0.36±1.2. Goniotomy was performed as the initial
surgical  procedure  in  29  eyes  (42%),  combined
trabeculotomy-trabeculectomy  in  17  eyes  (24.6%),
trabeculectomy in seven eyes (10%), trabeculotomy in six
eyes (8.7%), and surgical data were not available for eight
eyes (11.6%). Forty-two eyes (60.8%) needed more than one
surgery, and eight eyes (11.5%) required the implantation of
the Ahmed valve.
Analysis of CYP1B1 mutations: Mutations in the promoter
region and the three exons of CYP1B1 were analyzed by direct
PCR sequencing in a total 109 people, which consisted of 39
affected by PCG and 70 unaffected relatives of the patients.
No mutations segregating with the disease were found in the
promoter region. We identified a total of 16 distinct DNA
mutations in 13 (34.2%) of the 38 unrelated index cases: six
transitions (2 G>A and 4 C>T), six transversions (3 C>A, 1
T>A  and  2  G>T),  three  small  deletions,  and  one  small
duplication  (Table  2  and  Figure  1).  The  transitions  and
transversions predicted nine missense (P52L, G61E, Y81N,
A106D, F261L, R390S, P400S, P437L, and R469W) and
three nonsense (E262X, W341X, and E173X) amino acid
substitutions (Table 2 and Figure 1). On the other hand, the
conceptual  translation  of  one  nucleotide  long  and  13
nucleotide  long  deletions  (c.906delG  and  c.
1435_1447delGAGTGCAGGCAGA, respectively) as well as
one  10  nucleotide  long  duplication  (c.
1571_1580dupTCATGCCACC) resulted in three frameshift
mutations followed by stop codons in the new reading frame
(A179fsX18,  T404fsX30,  and  R355fsX69,  respectively;
Table  2).  Besides,  the  six  nucleotide  long  deletion  (c.
907_912delACCCAA) predicted a two amino acid deletion,
K513_P514del (Table 2 and Figure 1). To the best of our
knowledge, 6 of the 14 mutations were novel (A106D, E173X,
F261L, E262X, W341X, and K513_P514del; Figure 1). None
of  these  six  novel  mutations  was  found  in  325  (650
chromosomes) unrelated control subjects. The highest allelic
frequency among PCG index cases with CYP1B1 mutations
corresponded  to  mutations  T404fsX30  (23.0%)  and
R355fsX69 (11.5%; Table 2).
Most  of  these  mutations  were  found  in  compound
heterozygous subjects (85.7%). Nonetheless, we identified
two index cases (14.3%) that were heterozygous for mutations
P52L and Y81N (families PCG 3 and PCG 4, respectively;
Figure 2). In contrast and as expected, relatives of these two
patients who were heterozygotes for mutations Y81N and
P52L were phenotypically normal (Figure 2). An intriguing
finding was that three compound heterozygotes did not show
any type of glaucoma at the time of the study. Two of them
were siblings carrying mutations P52L and E229K (family
PCG 3, subjects III:1 and III:2; Figure 2) while the third
relative carried mutations E229K and R469W (family PCG
25, subject I:1; Figure 2). The age of these patients at the time
of the study ranged from 28 to 58 years. Therefore, they likely
represent cases of incomplete penetrance, which has been well
documented in PCG [2,4,12,41]. It is interesting to note that
mutation E229K was present in the three cases of incomplete
penetrance detected in this study.
Mutations R355fsX69 and F261L were identified in the
compound heterozygous state in the index case of family PCG
1 (IV:2) who manifested the disease at the time of birth (Figure
2). These mutations were also present in the heterozygous
state  in  11  unaffected  carriers  from  the  same  pedigree.
However, the oldest F261L carrier (I:1; 83 years old at the
time of the study) was diagnosed with ocular hypertension
(OHT) during the study, although we cannot rule out that this
finding was merely a coincidence. Similarly, several normal
heterozygous  carriers  of  mutations  G61E  and  T404fsX30
were identified in families PCG 2 and PCG 5.
Family PCG 25 also presented two affected siblings who
who were compound heterozygotes with the same genotype
(R469W/T404fsX30; Figure 2). As previously mentioned,
their father could represent a case of incomplete penetrance.
The affected woman, II:2, married an unrelated blind man
diagnosed  with  PCG  (PCG  25b,  Figure  2)  who  had  no
mutations in either CYP1B1 or MYOC. Two affected siblings
were  present  in  family  PCG  29,  the  index  case  was  a
compound  heterozygote  (E262X/P513_K514del),  but  we
were unable to perform DNA analysis in her affected sister
(Figure 2). The index cases from families PCG 32 and PCG
34  were  also  compound  heterozygotes.  We  ruled  out  the
presence of mutations in the coding region of MYOC in all the
families (data not shown).
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421Haplotype analysis: Analysis of 4 coding common CYP1B1
SNPs  (R48G,  A199S,  V432L,  and  N453S)  revealed  that
RAVN was the most common haplotype (65.6%) among the
Spanish patients who carried CYP1B1 mutations. In addition,
RAVN  was  the  haplotype  background  in  10  of  the  16
identified mutations (Table 2).
Evaluation of novel mutated positions by multiple sequence
alignment:  To  evaluate  the  degree  of  phylogenetic
conservation of the novel mutated amino acid residues and the
possible impact of the novel mutations in the structure and
function  of  the  protein,  we  compared  the  amino  acid
sequences of some mammalian and fish CYP1B1 enzymes
and  also  two  of  the  mammalian  members  of  the  well
characterized CYP1A1 and CYP1A2 subfamilies (Figure 3).
All the novel mutations affected highly conserved amino acid
residues  (Figure  3).  The  three  nonsense  mutations  were
predicted to truncate the protein at helices D, G, and I whereas
the deletion of two amino acids (P513_K514del) affected the
beta  3.2-sheet.  These  mutations  are  likely  to  produce  a
complete  loss-of-function  of  the  protein.  The  two  novel
missense mutations were located in helices B (A106D) and G
(F261L; Figure 3).
Functional analysis of CYP1B1 mutations: To experimentally
assess the effect of the mutations on the function of CYP1B1
and to analyze whether different levels of enzymatic activity
correlate with the phenotype, we analyzed their enzymatic
activity and protein stability. We were able to clone a total of
nine  mutations  (three  of  them  novel)  by  site-directed
mutagenesis as described in the Methods. CYP1B1 enzymatic
activity was estimated by determining the EROD activity in
transfected HEK-293T cells with a fluorimetric assay at 2 h
after addition of the substrate. Eight mutants showed reduced
enzymatic activity compared with the wild-type protein while
P400S  showed  normal  activity  (Figure  4A).  Variants
displaying an activity below 1% of the wild-type (E173X,
F261L, E262X, and R469W) were classified as null alleles,
and those with enzymatic activity ranging from 20% to 40%
of wild-type CYP1B1 (P52L, G61E, Y81N, and E229K) were
considered hypomorphic variants (Figure 4A). Detection of
CYP1B1  in  cells  by  western  blot  analysis  2  h  after  the
enzymatic  assay  showed  reduced  protein  levels  for  the
following CYP1B1 mutants: G61E, Y81N, E262X, P400S,
and R469W (Figure 4B). GFP analysis showed that there were
no significant differences in transfection efficiency. These
data indicate that although mutation P400S does not reduce
the  catalytic  activity,  it  impairs  protein  stability,  likely
resulting in reduced enzymatic activity levels over time.
We then specifically investigated the protein stability of
these mutants using transiently transfected HEK-293T cells
that  were  treated  with  the  protein  synthesis  inhibitor,
cycloheximide, at various time points. Cells appeared viable
upon microscopic examination at the latest time point used (8
h). We observed that the amount of all the CYP1B1 variants
decreased  upon  exposure  to  cycloheximide,  but  the
degradation  of  all  the  mutants  was  significantly  more
pronounced than that of the wild-type protein (Figure 5). Eight
Figure 1. Detection of six novel CYP1B1 mutations in Spanish PCG families by direct PCR DNA sequencing. Sequencing results of probands
from families PCG 45 (A), PCG 28 (B), PCG 1 (C), PCG 29 (D), PCG 34 (E), and PCG 32 (F). Control electropherograms are shown for
comparison purposes. The arrows indicate the position of mutations.
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422hours after cycloheximide exposure, the relative amount of
wild-type CYP1B1 was 78% of the initial value (Time 0)
while the protein level for three mutants was lower than 5%
(G61E, Y81N, and E262X; Figure 5). A second group of
mutants (P52L and E229K) showed protein levels close to
20% of the initial value. The amount of E173X, P400S, and
R469W was around 40% while F261L showed the highest
relative value among mutants (55%; Figure 5). Interestingly,
although the last mutation did not strongly affect the stability
of the polypeptide chain after 8 h of cycloheximide treatment,
it  completely  inactivated  the  catalytic  activity.  However,
mutation P400S, which did not impair the catalytic activity,
significantly reduced the CYP1B1 protein levels to about 35%
of  the  initial  value.  These  data  show  that  the  CYP1B1
mutations associated with PCG impair the function of the
cytochrome P450 molecule by affecting their catalytic activity
and/or protein stability to different extents, thus supporting
that  different  levels  of  residual  CYP1B1  activity  might
underlie  the  development  of  the  disease  and  phenotypic
variability.
Genotype-phenotype correlation: To analyze the genotype-
phenotype relationship, we first compared the clinical features
Figure  2.  Pedigrees  of  PCG  Spanish
families  with  CYP1B1  mutations.
Genotypes  are  indicated  below  the
symbols.  DNA  samples  were  not
available from the parents of probands
in families PCG 29, PCG 32, and PCG
34. Therefore, their genotypes could not
be  determined.  Arrows  show  the
probands.  Black  and  gray  symbols
indicate  PCG  and  OHT  phenotypes,
respectively. +: wild-type allele.
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423between PCG patients who carried CYP1B1 mutations and
those with no identified CYP1B1 or MYOC mutations (Table
3). The percentage of bilateral cases, age at diagnosis, and
male/female ratio did not differ significantly between the two
groups. The mean IOP values in the affected eyes were higher
among mutation carriers (26.8±7.8 mmHg) than among non-
carriers (23.1±7.9 mmHg), although the differences were not
significant (p=0.083). We then compared clinical parameters
between patients with two CYP1B1 null alleles and the rest of
the carriers. Interestingly, the first group was of a younger
mean age at diagnosis that those who carried at least one
hypomorphic  allele  (0.6±0.9  months  versus  17.3±15.2
months, respectively; p<0.05). Although patients with two
null alleles showed higher mean IOP values at diagnosis and
higher  mean  C/D  ratios  than  patients  with  at  least  one
hypomorphic  allele,  the  differences  were  not  significant.
There  were  no  significant  differences  noted  for  the  three
groups of patients with regard to the mean number of filtration
surgeries required to control IOP (Table 3). All these data
indicate that CYP1B1 null mutations are associated with the
severe PCG phenotypes mainly characterized by a very young
age at diagnosis.
DISCUSSION
CYP1B1 mutations in primary congenital glaucoma in Spain:
Human CYP1B1 has been implicated in primary congenital
glaucoma in different human populations. However, the role
of this gene in Spanish patients has not yet been investigated,
and the number of studies performed in European populations
is still low. Here, we report the first molecular and functional
analysis of CYP1B1 mutations in Spanish PCG patients. The
findings, particularly those arising from functional studies,
may have some general implications for understanding the
pathogenesis of the disease. Our data show that around 34%
of the studied index cases with autosomal recessive PCG carry
mutations in this gene. This value is within the range found in
groups of patients from different countries, around 10% in
Mexico  [42]  and  Ecuador  [43];  20%  in  Indonesia  [17],
Australia [18], and Japan [19]; around 40% in Turkish patients
[6]; approximately 50% in Brazil [20] and France [21]; and
about  100%  in  consanguineous  Saudi  Arabian  [4]  and
Slovakian Gypsy [22] patients. These data illustrate that the
contribution of defects in this gene varies significantly among
human  populations,  which  highlights  that  analyzing  large
groups of PCG from different ethnic backgrounds is required
to ascertain the role of this gene in specific human groups. We
also  found  an  elevated  proportion  of  compound  CYP1B1
heterozygosity  and  allelic  heterogeneity  among  Spanish
patients. In this regard, a total of 16 different mutations were
identified. To the best of our knowledge six of them were
novel.
Mutation G61E has been previously identified in PCG
patients from Saudi Arabia [2], Morocco [44], Mexico [42],
and Turkey [6]. Variant Y81N was identified in Spanish [26]
Figure 3. Location of six novel CYP1B1
mutations  found  in  PCG  patients.  A:
Scheme of the CYP1B1 gene showing
the  position  of  the  novel  mutations
identified in this study. The three exons
are represented by boxes, and different
conserved structural domains encoded
by  them  are  depicted  in  pink.  B:
Multiple  amino  acid  sequence
alignment  of  CYP1B1,  CYP1A1  and
CYP1A2  from  different  species.  The
three exons are represented by boxes,
and  different  conserved  structural
domains encoded by them are depicted
by  different  patterns  and  shadings.
Sequence alignment was generated by
ClustalW. Arrows indicate the residues
affected  by  mutations.  Different
structural  domains  of  the  cytochrome
P450  superfamily  are  indicated.
Asterisks indicate amino acid positions
at  which  all  query  sequences  are
identical. Amino acid positions at which
all the analyzed sequences had amino
acids that were chemically similar are
denoted by two dots (:). One dot denotes
amino  acid  positions  with  weak
chemical similarity (.).
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424and French [25] POAG cases. Mutation P400S has previously
been reported in the homozygous state in only one Australian
PCG patient of Indian descent [18]. Interestingly, the father
of this Australian PCG case was diagnosed with juvenile onset
open-angle glaucoma and was heterozygous for this mutation,
thus supporting the pathogenicity of this variant and showing
that  it  is  associated  with  different  glaucoma  phenotypes.
Mutation P52L was initially described in a Spanish patient
with  POAG  and  also  in  a  66-year-old  subject  who  was
clinically normal at the time of the study [26]. Recently, it has
been found as a loss-of-function mutation in German POAG
patients and in one patient with hepatocellular adenoma [45].
Mutation  P437L  has  been  reported  in  PCG  patients  from
Brazil [20], Turkey [12], and India [46]. It is noteworthy that
these three PCG mutations (P400S, P52L, and P437L) were
previously  found  in  patients  with  POAG,  showing  their
association with different glaucoma phenotypes.
Haplotype background: Most of the mutations identified in
this study were embedded in the same haplotype (RAVN). It
has been reported that founder effects must have occurred for
most CYP1B1 mutations [47]. Our data agree with the founder
effect hypothesis, but as this haplotype is the most common
in the Spanish population, present in 37% of normal subjects
(unpublished  results),  an  extended  haplotype  analysis  is
required to confirm this hypothesis.
Phylogenetic and functional analysis: All the novel mutations
identified in this study affect highly evolutionary conserved
amino acid residues and were predicted either to truncate the
protein  or  to  alter  the  physicochemical  properties  of  the
affected amino acids, supporting their pathogenic character.
In that sense, mutation A106D changed a non-polar amino
acid  for  a  residue  with  a  negative  charge  while  F261L
substituted a large and aromatic amino acid for an aliphatic
residue. These mutations were located in helices B, D, G, and
I  and  in  the  beta  3.2-sheet,  which  are  structurally  and
functionally relevant. Helices B and D are relatively well
conserved structurally [48]. The G helix forms part of the
substrate access channel [49], and the I-helix of the heme-
binding region contains catalytically important residues [49].
The COOH-terminal half of helix I and the beta 3.2-sheet
belong  to  the  most  structurally  conserved  regions  in
cytochrome  P450  [48].  Analysis  of  the  EROD  enzymatic
activity  demonstrated  a  complete  loss-of-function  of  four
mutants (E173X, F261L, E262X, and R469W), which clearly
Figure 4. Effect of CYP1B1 mutations
found  in  Spanish  PCG  patients  on
CYP1B1  catalytic  activity.  A:  cDNA
constructs  encoding  the  different
mutations were transiently expressed in
HEK-293T  cells.  Transfection
efficiency  was  assessed  by  co-
transfection  with  a  cDNA  construct
encoding  GFP.  The  EROD  activity,
expressed as a percentage of the activity
of the wild-type protein, was measured
as  indicated  in  Methods.  Error  bars
represent  the  SEM  of  triplicate
experiments.  B:  Protein  levels  of  the
different  CYP1B1  mutants  present  in
transiently transfected HEK-293T cells
2 h after the enzymatic assay are shown
as  a  control  of  protein  expression.
CYP1B1 polypeptides, tagged with the
myc  epitope  at  their  COOH-terminal
end,  were  detected  by  western
immunoblot using a monoclonal anti-
myc antibody (Santa Cruz). GFP was
detected  using  an  anti-GFP  antibody
(Santa Cruz).
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425demonstrates that they are null alleles. In addition, the null
alleles differed in protein stability. E262X was highly unstable
while E173X, F261L, and R469W were moderately unstable.
As all these mutations result in inactive enzyme variants, it is
unlikely that the differences on stability may influence the
phenotypic  outcome.  Most  hypomorphic  alleles  (P52L,
G61E,  Y81N,  and  E229K)  displayed  reduced  catalytic
activity  and  protein  instability  (protein  level  after  8  h  of
protein synthesis inhibition less than 20% of the level at the
initial time). Nonetheless, P400S showed normal catalytic
activity and a significant reduction of protein stability. All
these allele-dependent differences in enzymatic activity and
protein  stability  could  contribute  to  explain  cases  of
incomplete penetrance as we will discuss later.
Few functional studies of pathogenic CYP1B1 mutations
have previously been reported. In accordance with our results,
one of these studies found that mutants G61E and R469W
have reduced enzymatic activity (50% and 30%, respectively)
toward steroid hormones as substrates [33]. Regarding protein
stability, Jansson and co-workers performed a study using
membrane  preparations  obtained  from  bacteria  expressing
recombinant CYP1B1 mutants [33]. They found that G61E
was much less stable than the wild-type protein (the CYP1B1
level decreased about 50%, after 24 h storage at 4 ºC). Unlike
our results, however, they reported that R469W was as stable
as the wild type enzyme. This discrepancy could be due to
different experimental settings since in the present study we
measured CYP1B1 levels in eukaryotic cells after inhibiting
protein synthesis with cycloheximide. A second report also
classified  Y81N  and  E229K  as  hypomorphic  alleles  and
proposed that these two sequence variants could function as
risk alleles, which can lead to the development of glaucoma
in the presence of modifier genes or environmental influence
[34]. These two mutations have also been found to reduce
protein stability, although while Y81N severely inhibits the
turnover of various substrates, E229K impacts the ability to
metabolize substrates moderately depending on the type of
substrate [35].
Incomplete penetrance and hypomorphic alleles: Incomplete
penetrance  has  been  associated  with  several  CYP1B1
mutations  including  G61E,  R368H,  D374N,  R469W,  g.
4340delG, C209R, and g.4238del10 [2,4,41]. Interestingly,
we observed three compound heterozygotes with incomplete
penetrance in families PCG 3 and PCG 25 who carried at least
one  copy  of  the  hypomorphic  alleles  P52L  or  E229K.  In
accordance with Bejjani and coworkers [4] and as mentioned
before, we speculate that residual enzymatic activity from
hypomorphic alleles in these subjects could be sufficient to
maintain the normal phenotype either alone or in cooperation
with compensating variants of unknown modifier genes and/
or the increased CYP1B1 expression induced by compounds
present in the environment and/or the diet. In line with these
ideas, it has also been proposed that reduced penetrance could
be due to a dominant suppressor of the PCG phenotype, which
is  not  linked  genetically  to  CYP1B1  [2],  and/or  to  the
inducibility of CYP1B1 by environmental lipophilic agents to
which  individuals  may  have  been  exposed  [33].  In  fact,
CYP1B1 is inducible upon activation of the aryl hydrocarbon
receptor by the binding of ligands such as polycyclic aromatic
hydrocarbons [50,51] and by compounds found in certain
vegetables [52]. According to the present results and to our
hypothesis,  mutation  E229K  accompanied  by  c.1064–
Figure  5.  Time  course  stability  of
CYP1B1 mutant polypeptides found in
Spanish PCG patients. cDNA constructs
encoding the different mutations were
transiently  expressed  in  HEK-293T
cells.  Cells  were  treated  with
cycloheximide,  a  protein  synthesis
inhibitor, and the amount of the different
CYP1B1 polypeptides, tagged with the
myc  epitope  at  their  COOH-terminal
ends, were determined by densitometry
of the signals detected in western blots
using an anti-myc monoclonal antibody
(Santa  Cruz)  at  the  indicated  time
points.  Transfection  efficiency  was
assessed  by  co-transfection  with  a
cDNA construct encoding GFP. When
required, CYP1B1 protein levels were
corrected  for  transfection  efficiency.
Relative  amounts  of  CYP1B1  are
expressed as a percentage of levels at
time 0 h. Error bars represent the SEM
of triplicate experiments.
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4271076del (likely a null allele) has also been identified in a
normal  carrier  [47].  Incomplete  penetrance,  particularly
although  not  exclusively  associated  with  hypomorphic
CYP1B1 alleles, indicates that PCG is not a simple recessive
trait and underscores its multifactorial character at least in a
subset of patients. However, the glaucoma phenotype could
be less variable and therefore, more predictable in patients
who carry completely inactive CYP1B1 alleles. Incomplete
penetrance associated with partial loss of protein function
originated by structural mutations has also been reported in
diseases such as in familial retinoblastoma [53,54].
Heterozygous  CYP1B1  mutations  in  primary  congenital
glaucoma: Another intriguing finding that apparently does not
match a typical recessive pattern of inheritance is the presence
of heterozygous CYP1B1 mutations in PCG patients. This
situation has been previously reported [35]. According to our
data, mutation Y81N in the heterozygous state has also been
described in a German PCG patient [47]. Moreover, E229K,
R368H, and R469W were reported as the only mutant allele
in Turkish PCG patients [6], and E229K has been identified
in the heterozygous state in two unrelated French patients
affected by PCG [21], in five Indian patients [55], in one
Turkish  case  [6],  and  in  one  Caucasian  patient  [41].
Interestingly, some of these mutations in the heterozygous
state are also associated with the milder POAG phenotype in
patients  from  Spain  [26],  France  [25],  and  India  [24,56].
Recently,  the  presence  of  double  heterozygous  variants,
CYP1B1 and FOXC1, has been described in two PCG cases,
although the role of possible digenism in disease causation is
yet to be established [15]. Once again, defective variants of
modifier  genes  and/or  environmental  compounds  could
cooperate with loss-of-function CYP1B1 alleles to produce
the disease phenotype. However, further work is required to
unravel this point.
Genotype-phenotype  correlation:  Previous  studies  have
reported  that  the  age  at  diagnosis  in  PCG  patients  with
CYP1B1  mutations  is  younger  than  for  patients  without
mutations [57]. Our data show that although the disease was
diagnosed earlier in carriers of CYP1B1 mutations than in non-
carriers,  the  differences  found  were  not  significant.  We
reasoned that patients with two null CYP1B1 alleles, which
means there is no CYP1B1 catalytic activity, could present
more  severe  phenotypes  than  carriers  of  at  least  one
hypomorphic allele, who likely conserve residual enzymatic
activity levels. According to this hypothesis, our results show
that PCG patients with a complete loss of CYP1B1 enzymatic
activity display the most severe disease phenotype featured
by very early mean onset of the disease (0.6±0.9 months). We
also  observed  higher  mean  IOP  values  and  optic  disc
excavations in this group of patients, but the differences were
not statistically significant. In accordance with the idea of
associating  the  worst  phenotypes  with  null  CYP1B1
mutations, the percentage of severe phenotypes in at least one
eye  have  been  reported  to  be  associated  with  various
mutations  ranging  from  100%  for  a  frameshift  mutation
(376insA) producing a truncated protein at codon 223 (null
allele)  to  approximately  62%–83%  for  different  missense
mutations such as G61E, P193L, E229K, R368H, and R390C
[55]. According to our data, two of these mutations (G61E and
E229K) are hypomorphic alleles. Moreover, E229K has been
found as the only CYP1B1 allele in a PCG case with moderate
goniodysgenesis [41]. Further studies with a larger number of
patients  will  be  required  to  confirm  whether  in  fact  the
complete absence of CYP1B1 activity correlates with the
worst phenotype.
The identification of a panel of 16 different CYP1B1
mutations for the first time in Spanish PCG patients with allele
dependent functional heterogeneity could provide a basis to
better understanding of the disease as well as to improve
genetic testing and genetic PCG counseling. This in turn will
contribute to early diagnosis and prevention of blindness,
which can result from a late diagnosis of PCG. Hopefully, this
will  reduce  the  burden  of  the  afflicted  families  and  will
improve their quality of life since it has been shown that early
and prompt surgical interventions in PCG patients leads to a
better prognosis [58,59]. Finally, our data clearly indicate that
other  genetic  and/or  environmental  factors  remain  to  be
identified,  particularly  in  patients  carrying  hypomorphic
mutations.
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